Balance Sheet
Cash Flow Statement
AcquisitionsAmortization of Deferred ChargesAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Discontinued OperationsCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Mimedx Group (MDXG) Asset Writedowns and Impairment: 2012-2024

Historic Asset Writedowns and Impairment for Mimedx Group (MDXG) over the last 9 years, with Dec 2024 value amounting to $595,000.

  • Mimedx Group's Asset Writedowns and Impairment rose 836.92% to $2.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $3.6 million, marking a year-over-year increase of 322.89%. This contributed to the annual value of $595,000 for FY2024, which is 58.94% down from last year.
  • Mimedx Group's Asset Writedowns and Impairment amounted to $595,000 in FY2024, which was down 58.94% from $1.4 million recorded in FY2023.
  • Mimedx Group's Asset Writedowns and Impairment's 5-year high stood at $2.8 million during FY2022, with a 5-year trough of $100,000 in FY2021.
  • For the 3-year period, Mimedx Group's Asset Writedowns and Impairment averaged around $1.6 million, with its median value being $1.4 million (2023).
  • As far as peak fluctuations go, Mimedx Group's Asset Writedowns and Impairment slumped by 90.26% in 2021, and later surged by 2,720.00% in 2022.
  • Yearly analysis of 5 years shows Mimedx Group's Asset Writedowns and Impairment stood at $1.0 million in 2020, then plummeted by 90.26% to $100,000 in 2021, then soared by 2,720.00% to $2.8 million in 2022, then crashed by 48.62% to $1.4 million in 2023, then slumped by 58.94% to $595,000 in 2024.